RecruitingNot ApplicableNCT07273773

Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction

Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) A Prospective, Multicenter, Single-Arm Performance-Goal Study


Sponsor

Rigicon, Inc.

Enrollment

182 participants

Start Date

Jan 26, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction. The study follows patients implanted with the Rigicon Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis for up to 3 years after implantation.


Eligibility

Sex: MALEMin Age: 22 Years

Inclusion Criteria4

  • Male ≥22 years of age.
  • Diagnosed with erectile dysfunction (impotence).
  • Agree to receive Infla10® three-piece IPP as an ED treatment.
  • Willing to complete all protocol required for follow-up visits and tests.

Exclusion Criteria21

  • Contraindication to general anesthesia.
  • Known allergy or sensitivity to product materials as indicated in the device labeling.
  • Previous penile prosthesis or prior enlargement surgeries
  • Diagnosed penile sensory neuropathy.
  • Patients who are receiving immunosuppressive drugs or have a history of kidney transplantation.
  • Patients who are receiving chemotherapy at the time of enrolment.
  • Diagnosed with fibrotic disease, such as priapism or Peyronie's disease or Chordee.
  • Compromised immune system, such as systemic lupus erythematosus, discoid lupus, or scleroderma.
  • Uncontrolled diabetes (HbA1c ≥ 9.0% \[≈75 mmol/mol\], measured within 90 days prior to surgery.
  • Bleeding disorder or coagulopathy that may in the judgment of the investigator preclude safe procedure.
  • Active urogenital infection or active skin infection in region of surgery or systemic infection at the time of assessment.
  • Clinically significant comorbidities or presence of unstable conditions (e.g. cardiovascular, lung, renal \[serum creatinine > 2.0 mg/dl\], hepatic, bleeding disorders, or metabolic impairment) that may confound the results of the study or in the judgment of the physician investigator preclude safe procedure.
  • Lacking manual dexterity or mental abilities necessary to operate the device.
  • Expected life expectancy < two years.
  • Unwilling or unable to sign the Informed Consent.
  • Unwilling or unable to comply with the follow-up study requirements.
  • Psychogenic erectile dysfunction
  • Currently participating in an investigational drug or another investigational device exemption (IDE) study.
  • The cognitively challenged subjects and subjects with any cognitive disorder that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affects the ability to complete the study questionnaires.
  • Incarcerated subjects
  • Subjects who are currently using, or who have not previously attempted and failed, standard non-surgical ED therapies including oral or topical treatments.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICERigicon Infla10® Inflatable Penile Prosthesis (IPP)

Medical Device: Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis • Other Names: Inflatable Penile Prosthesis (IPP) Treatment: Erectile dysfunction


Locations(7)

Perito Urology

Coral Gables, Florida, United States

Atlanta Cosmetic Urology

Atlanta, Georgia, United States

UroPartners

Chicago, Illinois, United States

Kramer Urology

Hyannis, Massachusetts, United States

Washington Heights Urology

New York, New York, United States

Urology Partners of North Texas

Arlington, Texas, United States

Vitality Urology Institute

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07273773


Related Trials